Engineering probiotics-derived membrane vesicles for encapsulating fucoxanthin: evaluation of stability, bioavailability, and biosafety

Liang, Duo; Liu, Chenyue; Li, Jiaxuan; Liu, Yu; Li, Jiashu; Tan, Mingqian; Su, Wentao

doi:10.1039/d2fo04116b

Cited by 7 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Utilizing probiotics-derived EVs as drug delivery carriers has gained tremendous attention in recent years. , Our previous studies have explored the use of engineered probiotic membrane-derived vesicles loaded with FX to combat ulcerative colitis. , However, the nonspecific delivery of probiotic vesicles resulted in broad distribution in various organs, greatly reducing the therapeutic effect for NAFLD. To overcome the issue, we have constructed a novel biomimic membrane vesicle FX delivery system via self-assembly with liver-targeting capacity for effective NAFLD intervention, as shown in Scheme .…”

Section: Resultsmentioning

confidence: 99%

“…Utilizing probiotics-derived EVs as drug delivery carriers has gained tremendous attention in recent years. 34,35 Our previous studies have explored the use of engineered probiotic membrane-derived vesicles loaded with FX to combat ulcerative colitis. 23,35 However, the nonspecific delivery of probiotic vesicles resulted in broad distribution in various organs, greatly reducing the therapeutic effect for NAFLD.…”

Section: ■ Materials and Methodsmentioning

confidence: 99%

“…35 UV−vis absorption spectrophotometer (PerkinElmer, Cambridge) to evaluate the load of FX. To evaluate the stability in vitro, FX, LpEVs-FX, and GA-LpEVs-FX were incubated in SGF for 4 h and SIF for 6 h…”

mentioning

confidence: 99%

See 2 more Smart Citations

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Wu,

Xiang,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Extracellular vesicles (EVs) possess favorable biocompatibility and immunological characteristics, making them optimal carriers for bioactive substances. In this study, an innovative hepatic-targeted vesicle system encapsulating with fucoxanthin (GA-LpEVs-FX) was successfully designed and used to alleviate nonalcoholic fatty liver disease. The formulation entails the self-assembly of EVs derived from Lactobacillus paracasei (LpEVs), modification with glycyrrhetinic acid (GA) via amide reaction offering the system liver-targeting capacity and loading fucoxanthin (FX) through sonication treatment. In vitro experiments demonstrated that GA-LpEVs-FX effectively mitigated hepatic lipid accumulation and attenuated reactive oxygen species-induced damage resulting lipid accumulation (p < 0.05). In vivo, GA-LpEVs-FX exhibited significant downregulation of lipogenesis-related proteins, namely, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC1), and sterol regulatory element binding protein 1 (SREBP-1), subsequently ameliorating lipid metabolism disorders (p < 0.05), and the stability of GA-LpEVs-FX significantly improved compared to free FX. These findings establish a novel formulation for utilizing foodborne components for nonalcoholic fatty liver disease alleviation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: ■ Materials and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Wu,

Xiang,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…The biodistribution of FEVs derived from probiotics seems similar to that of plant EVs. After 12 h of oral administration in mice, engineering probiotics‐derived membrane vesicles were mainly detected in the GI tract while weak signals were detected in the spleen and kidney (Liang et al., 2023 ).…”

Section: Food‐derived Extracellular Vesiclesmentioning

confidence: 99%

Gut‐liver axis: Potential mechanisms of action of food‐derived extracellular vesicles

Zhang,

Wang,

Tan

et al. 2024

J of Extracellular Vesicle

View full text Add to dashboard Cite

Food‐derived extracellular vesicles (FEVs) are nanoscale membrane vesicles obtained from dietary materials such as breast milk, plants and probiotics. Distinct from other EVs, FEVs can survive the harsh degrading conditions in the gastrointestinal tract and reach the intestines. This unique feature allows FEVs to be promising prebiotics in health and oral nanomedicine for gut disorders, such as inflammatory bowel disease. Interestingly, therapeutic effects of FEVs have recently also been observed in non‐gastrointestinal diseases. However, the mechanisms remain unclear or even mysterious. It is speculated that orally administered FEVs could enter the bloodstream, reach remote organs, and thus exert therapeutic effects therein. However, emerging evidence suggests that the amount of FEVs reaching organs beyond the gastrointestinal tract is marginal and may be insufficient to account for the significant therapeutic effects achieved regarding diseases involving remote organs such as the liver. Thus, we herein propose that FEVs primarily act locally in the intestine by modulating intestinal microenvironments such as barrier integrity and microbiota, thereby eliciting therapeutic impact remotely on the liver in non‐gastrointestinal diseases via the gut‐liver axis. Likewise, drugs delivered to the gastrointestinal system through FEVs may act via the gut‐liver axis. As the liver is the main metabolic hub, the intestinal microenvironment may be implicated in other metabolic diseases. In fact, many patients with non‐alcoholic fatty liver disease, obesity, diabetes and cardiovascular disease suffer from a leaky gut and dysbiosis. In this review, we provide an overview of the recent progress in FEVs and discuss their biomedical applications as therapeutic agents and drug delivery systems, highlighting the pivotal role of the gut‐liver axis in the mechanisms of action of FEVs for the treatment of gut disorders and metabolic diseases.

show abstract

Freeze‐Thaw Microfluidic System Produces “Themis” Nanocomplex for Cleaning Persisters‐Infected Macrophages and Enhancing Uninfected Macrophages

Su,

Yin,

Zhou

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Macrophages are the primary effectors against potential pathogen infections. They can be “parasitized” by intracellular bacteria, serving as “accomplices”, protecting intracellular bacteria and even switching them to persisters. Here, using a freeze‐thaw strategy‐based microfluidic chip, we created a “Themis” nanocomplex (TNC). The TNC consisted of Lactobacillus reuteri‐derived membrane vesicles, heme, and vancomycin, which cleaned infected macrophages and enhanced uninfected macrophages. In infected macrophages, TNC released heme that led to the reconstruction of the respiratory chain complexes of intracellular persisters, forcing them to regrow. The revived bacteria produced virulence factors that destroyed host macrophages (accomplices), thereby being externalized and becoming vulnerable to immune responses. In uninfected macrophages, TNC upregulated the TCA cycle and oxidative phosphorylation (OXPHOS), contributing to immunoenhancement. The combined effect of TNC of cleaning the accomplice (infected macrophages) and reinforcing uninfected macrophages provides a promising strategy for intracellular bacterial therapy.This article is protected by copyright. All rights reserved

show abstract

Engineering probiotics-derived membrane vesicles for encapsulating fucoxanthin: evaluation of stability, bioavailability, and biosafety

Abstract: Due to the multiplex absorption barrier in the gastrointestinal tract, the low oral bioavailability of many lipophilic chemicals limits their range of applications. Biomimetic nanovesicles offered unique advantages in overcoming...

Cited by 7 publications

References 45 publications

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Gut‐liver axis: Potential mechanisms of action of food‐derived extracellular vesicles

Freeze‐Thaw Microfluidic System Produces “Themis” Nanocomplex for Cleaning Persisters‐Infected Macrophages and Enhancing Uninfected Macrophages

Contact Info

Product

Resources

About